© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
July 07, 2021
The pivotal OASIS trial is examining the capability of the RENOVA iStim tibial neuromodulation system to reduce urinary urgency incontinence episodes in women.
July 05, 2021
A crude logistic regression analysis showed that adjunctive pharmacotherapy did not significantly change the odds of improving nocturia severity.
June 16, 2021
The national health insurance program is now covering Elitone, a surface-applied electrical muscle stimulation device for female stress urinary incontinence that patients self-administer at home.
May 21, 2021
Amplitude setting as low as 50% below sensory level is effective for treating overactive bladder.
May 19, 2021
The device can now be marketed throughout the EU, as well as in Iceland, Liechtenstein, and Norway.
May 10, 2021
The study also showed that sexual function was comparable for women with SUI who received single incision sling versus those who underwent transobturator midurethral sling.
April 27, 2021
The implantable tibial neuromodulation device is being assessed at 8 clinical sites in the United States.
April 15, 2021
Odds of having UI were 56% higher in women with vs women without diabetes.
April 13, 2021
Vibegron (Gemtesa) is approved by the FDA for the treatment of adult patients with overactive bladder with symptoms of urge urinary incontinence.
April 07, 2021
Ninety-eight percent of the study population was female.